Effect of Ulinastatin Combined With High-Volume Hemofiltration on Inflammatory Response and MODS Incidence in Severe Sepsis.

This study evaluated the impact of ulinastatin combined with high-volume hemofiltration (HVHF) on inflammation and the development of multiple organ dysfunction syndrome (MODS) in severe sepsis. One hundred patients with severe sepsis were recruited and allocated into two groups based on treatment methods (n = 50 patients). The control group underwent HVHF, while the observation group received ulinastatin-assisted HVHF. Comparisons of general data were made in treatment efficacy (APACHE II score), MODS score, and SOFA score. Inflammatory markers and organ function indicators were also measured before and after treatment. The incidence of disseminated intravascular coagulation (DIC), MODS, and mortality rates at 28 days were also analyzed. The observation group showed significantly reduced APACHE II, MODS, and SOFA scores, along with lower levels of IL-6, IL-10, TNF-α, ALT, and Scr (p < 0.05). Additionally, the observation group had lower incidences of DIC, MODS, and mortality (p < 0.05). Furthermore, elevated CD4+ and CD4+/CD8+ ratios while reduced CD8+ levels were noted in the observation group (p < 0.05). We demonstrate that ulinastatin combined with HVHF effectively reduces inflammatory levels in patients with severe sepsis, improves organ function, lowers the incidence of MODS and mortality, and enhances immune function.